Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period, followed by a 2-week follow-up period.


Clinical Trial Description

At a Screening Visit, patients who provide written informed consent will have screening procedures performed, including a complete medical history, medication history, physical examination, including height, weight, sitting blood pressure, pulse rate and temperature, and clinical laboratory tests. Disease activity will be assessed using tear meniscus (TM) height, tear break-up time (BUT), fluorescein staining (FS), Schirmer test, and the Dry Eye Symptom Score (DESS). Doses of artificial tears must be stable for >2 weeks prior to the Screening Visit. Eligible patients will begin a 2-week run-in period, during which time they will be instructed to discontinue use of all topical ophthalmic medications except for lubricant eye drops. Patients who successfully complete the 2-week run-in period will be randomized to their assigned medication (CF101 1 mg or matching placebo) to be taken orally every q12h for 12 weeks. Patients will return for assessments and a new supply of study medication at Weeks 2, 4, 8 and 12, and at Week 14 for a final follow-up assessment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00349466
Study type Interventional
Source Can-Fite BioPharma
Contact
Status Completed
Phase Phase 2
Start date January 2007
Completion date May 2009

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00883649 - Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye N/A
Completed NCT00717418 - Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease N/A
Completed NCT00128245 - Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca Phase 2
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Completed NCT04147650 - Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome Phase 2/Phase 3
Completed NCT01733992 - A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease Phase 1
Completed NCT00987727 - Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Phase 4
Completed NCT00788229 - Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Phase 2
Completed NCT00554879 - Acupuncture Treatment of Dry Eye N/A
Completed NCT00407043 - Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Phase 4
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2
Recruiting NCT03953703 - Levocarnitine for Dry Eye in Sjogren's Syndrome Phase 2
Withdrawn NCT03398018 - Repository Corticotropin Injection in Keratoconjunctivitis Sicca Phase 4
Recruiting NCT02066896 - Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome Phase 3
Completed NCT02139033 - A Phase 4 Study Investigating the Efficacy of Retaineā„¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Phase 4
Terminated NCT01213342 - Omega-3 Fatty Acid Supplements and Dry Eye N/A
Completed NCT00201981 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3
Completed NCT00201955 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3